BRAF and colorectal carcinoma: For instance, the TP53 gene is frequently dysregulated in CRC and is associated with resistance to current therapies leading to poor prognoses.19 Tumors with KRAS and BRAF mutations are also associated with worse prognoses in CRC patients.